TITLE

Increased risk of prostate cancer

AUTHOR(S)
Elliott, William T.
PUB. DATE
August 2011
SOURCE
Primary Care Reports;Aug2011 Pharmacology Watch, p1
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article reports that the U.S. Food and Drug Administration (FDA) has warned about the association between the 5-alfa reductase inhibitors finasteride and dutasteride and increased risk of high-grade prostate cancer. Finasteride and dutasteride are marketed for benign prostate hypertrophy. Both drugs significantly reduced the risk of low-grade prostate cancers only based on the Prostate Cancer Prevention Trial (PCPT) and the Reduction by Dutasteride of Prostate Cancer Events (REDUCE) trial.
ACCESSION #
65119923

 

Related Articles

  • Medication Safety and Reliability. FDA warns 5-ARIs may increase the risk of high-grade prostate cancer.  // Formulary;Aug2011, Vol. 46 Issue 8, p313 

    The article reports the U.S. Food and Drug Administration released a warning that two 5-alpha-reductase inhibitors (5-ARIs) may increase the risk of high-grade prostate cancer. The 5-ARIs finasteride and dutasteride are used for treating benign prostatic hyperplasia. Two clinical trials,...

  • 5-ARIs to reduce PCa risk: Urologists' views are mixed. Nash, Karen // Urology Times;Mar2011, Vol. 39 Issue 3, p36 

    The article presents opinion of various doctors on the U.S. Food and Drug Administration (FDA) committee's decision against the use of 5-alpha-reductase inhibitors to reduce prostate cancer risk. According to doctor Murali Ankem, results of studies conducted by the committee to know the effect...

  • Prostate cancer risk and 5-ARIs. Elliott, William T. // Infectious Disease Alert;Oct2013 Pharmacology Watch, p2 

    The article reports on a study published in the "New England Journal of Medicine" which found a 30% reduction in the rate of lower-grade prostate cancers and no overall difference in mortality rate for prostate cancer patients taking 5-alpha reductase inhibitor finasteride. The study concludes...

  • Prostate Medications and Cancer Risks -- New Evidence.  // Internal Medicine Alert;7/29/2013 Pharmacology Watch, p1 

    The article focuses on a study conducted in men with urinary tract symptoms which states that men who were treated with 5-alpha reductase inhibitors had a lower risk of prostate cancer and the Gleason score which is used to help evaluate the prognosis of men with prostate cancer was measured 2-7.

  • Prostate cancer risk and 5-ARIs. Elliott, William T. // Primary Care Reports;Oct2013 Pharmacology Watch, p2 

    The article focuses on the continued debate about the prostate cancer risk and the 5-alpha reductase inhibitors (5-ARIs).

  • Chantix and cardiovascular events. Elliott, William T. // Primary Care Reports;Aug2011 Pharmacology Watch, p2 

    The article reports on a warning issued by the U.S. Food and Drug Administration (FDA) regarding the use of the drug varenicline and increased risk of cardiovascular adverse events.

  • ARBs and cancer risk. Elliott, William T. // Primary Care Reports;Aug2011 Pharmacology Watch, p2 

    The article reports on the lack of evidence showing an association between angiotensin receptor blockers (ARBs) and increased risk of cancer events, according to the U.S. Food and Drug Administration (FDA).

  • Prostate cancer risk and 5-ARIs.  // Neurology Alert;Aug2013 Pharmacology Watch, p1 

    The article discusses the use of medications 5-alpha reductase inhibitors (5-ARI) finasteride (Proscar) and dutasteride (Avodart) in the treatment of prostate cancer. A trial found that the said drugs reduced prostate cancer rate by 25% but that the risk for high-grade prostate cancer also...

  • Finasteride and dutasteride: prostate cancer.  // WHO Drug Information;2012, Vol. 26 Issue 2, p112 

    The article reports on a safety advisory which was issued in 2012 by the agency Health Canada regarding a risk of developing a rare high grade type of prostate cancer which is associated with the drugs finasteride and dutasteride.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics